Edition:
India

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

8.75USD
2:29am IST
Change (% chg)

$-0.05 (-0.57%)
Prev Close
$8.80
Open
$8.85
Day's High
$8.90
Day's Low
$8.70
Volume
68,693
Avg. Vol
103,169
52-wk High
$14.73
52-wk Low
$6.25

Latest Key Developments (Source: Significant Developments)

Aduro Biotech reports Q3 loss per share $0.33
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Aduro Biotech Inc ::Aduro Biotech reports third quarter 2017 financial results.Q3 loss per share $0.33.Q3 revenue $3.8 million versus $3.8 million.Q3 revenue view $6.1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Aduro Biotech Inc - ‍ anticipated 2017 milestones include to initiate phase 1 multiple myeloma trial with bion-1301, an anti-April antibody​.  Full Article

Aduro Biotech Q2 earnings per share view $0.06 -- Thomson Reuters I/B/E/S
Thursday, 4 Aug 2016 

Aduro Biotech Inc : Aduro Biotech reports second quarter 2016 financial results . Q2 earnings per share $0.04 . Q2 revenue view $25.2 million -- Thomson Reuters I/B/E/S . Q2 revenue $39 million versus $9.9 million .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Aduro Biotech announces phase 2b eclipse trial misses primary endpoint in heavily pretreated metastatic pancreatic cancer
Monday, 16 May 2016 

Aduro Biotech Inc : Phase 2b trial did not meet primary endpoint of improvement in overall survival for patients with pancreatic cancer who had failed at least 2 prior therapies in metastatic setting .Aduro Biotech announces phase 2b eclipse trial misses primary endpoint in heavily pretreated metastatic pancreatic cancer.  Full Article

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody​